In the in vivo experiments, TRAIL-Cur-NPs group showed significant higher anti-tumor efficiency than free TRAIL + Cur group in subcutaneous HCT116 tumor model (p < .05), but in the in vitro cytotoxicity evaluation, TRAIL-Cur-NPs group exhibited almost the same cytotoxicity with free TRAIL + Cur group. The gene discussed is TNFSF10; the disease is neoplasm.